Transcatheter aortic valve implantation versus surgical aortic valve replacement in Chinese patients with intermediate and high surgical risk for aortic stenosis: a decision analysis on effect, affordability and cost-effectiveness

Objective Examine the cost-effectiveness of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for Chinese patients with severe aortic stenosis (AS) at intermediate and high surgical risk.Design A two-phase model, comprising a 1-month decision tree to simu...

Full description

Saved in:
Bibliographic Details
Main Authors: Chang Liu, Chong Chen, Chuanyu Gao, Xiaoyan Guo, Dan Hu, Tongfeng Chen, Yipin Zhao, Jiangtao Cheng, Yuhao Liu
Format: Article
Language:English
Published: BMJ Publishing Group 2024-11-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/11/e082283.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846160546891563008
author Chang Liu
Chong Chen
Chuanyu Gao
Xiaoyan Guo
Dan Hu
Tongfeng Chen
Yipin Zhao
Jiangtao Cheng
Yuhao Liu
author_facet Chang Liu
Chong Chen
Chuanyu Gao
Xiaoyan Guo
Dan Hu
Tongfeng Chen
Yipin Zhao
Jiangtao Cheng
Yuhao Liu
author_sort Chang Liu
collection DOAJ
description Objective Examine the cost-effectiveness of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for Chinese patients with severe aortic stenosis (AS) at intermediate and high surgical risk.Design A two-phase model, comprising a 1-month decision tree to simulate perioperative outcomes and a 5-year Markov model with monthly cycles to simulate long-term outcomes, has been developed to evaluate the cost-effectiveness of TAVI compared with SAVR for Chinese patients with AS at intermediate and high risk. The event rates for both phases are sourced from the Placement of Aortic Transcatheter Valves IA and IIA trials, while the cost inputs and utility values are sourced from local sources or published literature. Adjustments for inflation were made using consumer price indexes for healthcare to enhance precision. To ensure the reliability and robustness of the model, sensitivity analyses were conducted to assess their impact on outcomes.Setting China healthcare system perspective.Participants A hypothetical cohort of Chinese patients with AS in intermediate and high surgical risk.Interventions TAVI versus SAVR.Outcome measures Cost, quality-adjusted life-years (QALYs), life-years gained and incremental cost-effectiveness Ratio (ICER).Result For both intermediate- and high-risk AS patients, offering TAVR resulted in high healthcare costs but moderate benefits compared with SAVR. Specifically, in the intermediate-risk population, TAVR led to a 0.34 QALY increase over SAVR, with an incremental cost of $16 707.58, resulting in an ICER of $49 176.60/QALY. Similarly, in the high-risk population, TAVR showed a 0.15 QALY increase over SAVR, with an incremental cost of $18 093.52, leading to an ICER of $122 696.37/QALY. However, both ICERs exceeded the willingness-to-pay threshold of $37 654.50/QALY. Sensitivity analyses confirmed the model’s stability under parameter uncertainty.Conclusion TAVI was deemed not cost-effective compared with SAVR for patients with AS at intermediate or high surgical risk in the Chinese healthcare system. Lowering valve costs was considered an effective approach to improve the cost-effectiveness of TAVI.
format Article
id doaj-art-72bf69130d844c38a9fbcacf335e0ddc
institution Kabale University
issn 2044-6055
language English
publishDate 2024-11-01
publisher BMJ Publishing Group
record_format Article
series BMJ Open
spelling doaj-art-72bf69130d844c38a9fbcacf335e0ddc2024-11-22T06:10:09ZengBMJ Publishing GroupBMJ Open2044-60552024-11-01141110.1136/bmjopen-2023-082283Transcatheter aortic valve implantation versus surgical aortic valve replacement in Chinese patients with intermediate and high surgical risk for aortic stenosis: a decision analysis on effect, affordability and cost-effectivenessChang Liu0Chong Chen1Chuanyu Gao2Xiaoyan Guo3Dan Hu4Tongfeng Chen5Yipin Zhao6Jiangtao Cheng7Yuhao Liu8Department of Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, Henan, ChinaDepartment of Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, Henan, ChinaDepartment of Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, Henan, ChinaDepartment of Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, Henan, ChinaDepartment of Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, Henan, ChinaDepartment of Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, Henan, ChinaDepartment of Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, Henan, ChinaDepartment of Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, Henan, ChinaDepartment of Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, Henan, ChinaObjective Examine the cost-effectiveness of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for Chinese patients with severe aortic stenosis (AS) at intermediate and high surgical risk.Design A two-phase model, comprising a 1-month decision tree to simulate perioperative outcomes and a 5-year Markov model with monthly cycles to simulate long-term outcomes, has been developed to evaluate the cost-effectiveness of TAVI compared with SAVR for Chinese patients with AS at intermediate and high risk. The event rates for both phases are sourced from the Placement of Aortic Transcatheter Valves IA and IIA trials, while the cost inputs and utility values are sourced from local sources or published literature. Adjustments for inflation were made using consumer price indexes for healthcare to enhance precision. To ensure the reliability and robustness of the model, sensitivity analyses were conducted to assess their impact on outcomes.Setting China healthcare system perspective.Participants A hypothetical cohort of Chinese patients with AS in intermediate and high surgical risk.Interventions TAVI versus SAVR.Outcome measures Cost, quality-adjusted life-years (QALYs), life-years gained and incremental cost-effectiveness Ratio (ICER).Result For both intermediate- and high-risk AS patients, offering TAVR resulted in high healthcare costs but moderate benefits compared with SAVR. Specifically, in the intermediate-risk population, TAVR led to a 0.34 QALY increase over SAVR, with an incremental cost of $16 707.58, resulting in an ICER of $49 176.60/QALY. Similarly, in the high-risk population, TAVR showed a 0.15 QALY increase over SAVR, with an incremental cost of $18 093.52, leading to an ICER of $122 696.37/QALY. However, both ICERs exceeded the willingness-to-pay threshold of $37 654.50/QALY. Sensitivity analyses confirmed the model’s stability under parameter uncertainty.Conclusion TAVI was deemed not cost-effective compared with SAVR for patients with AS at intermediate or high surgical risk in the Chinese healthcare system. Lowering valve costs was considered an effective approach to improve the cost-effectiveness of TAVI.https://bmjopen.bmj.com/content/14/11/e082283.full
spellingShingle Chang Liu
Chong Chen
Chuanyu Gao
Xiaoyan Guo
Dan Hu
Tongfeng Chen
Yipin Zhao
Jiangtao Cheng
Yuhao Liu
Transcatheter aortic valve implantation versus surgical aortic valve replacement in Chinese patients with intermediate and high surgical risk for aortic stenosis: a decision analysis on effect, affordability and cost-effectiveness
BMJ Open
title Transcatheter aortic valve implantation versus surgical aortic valve replacement in Chinese patients with intermediate and high surgical risk for aortic stenosis: a decision analysis on effect, affordability and cost-effectiveness
title_full Transcatheter aortic valve implantation versus surgical aortic valve replacement in Chinese patients with intermediate and high surgical risk for aortic stenosis: a decision analysis on effect, affordability and cost-effectiveness
title_fullStr Transcatheter aortic valve implantation versus surgical aortic valve replacement in Chinese patients with intermediate and high surgical risk for aortic stenosis: a decision analysis on effect, affordability and cost-effectiveness
title_full_unstemmed Transcatheter aortic valve implantation versus surgical aortic valve replacement in Chinese patients with intermediate and high surgical risk for aortic stenosis: a decision analysis on effect, affordability and cost-effectiveness
title_short Transcatheter aortic valve implantation versus surgical aortic valve replacement in Chinese patients with intermediate and high surgical risk for aortic stenosis: a decision analysis on effect, affordability and cost-effectiveness
title_sort transcatheter aortic valve implantation versus surgical aortic valve replacement in chinese patients with intermediate and high surgical risk for aortic stenosis a decision analysis on effect affordability and cost effectiveness
url https://bmjopen.bmj.com/content/14/11/e082283.full
work_keys_str_mv AT changliu transcatheteraorticvalveimplantationversussurgicalaorticvalvereplacementinchinesepatientswithintermediateandhighsurgicalriskforaorticstenosisadecisionanalysisoneffectaffordabilityandcosteffectiveness
AT chongchen transcatheteraorticvalveimplantationversussurgicalaorticvalvereplacementinchinesepatientswithintermediateandhighsurgicalriskforaorticstenosisadecisionanalysisoneffectaffordabilityandcosteffectiveness
AT chuanyugao transcatheteraorticvalveimplantationversussurgicalaorticvalvereplacementinchinesepatientswithintermediateandhighsurgicalriskforaorticstenosisadecisionanalysisoneffectaffordabilityandcosteffectiveness
AT xiaoyanguo transcatheteraorticvalveimplantationversussurgicalaorticvalvereplacementinchinesepatientswithintermediateandhighsurgicalriskforaorticstenosisadecisionanalysisoneffectaffordabilityandcosteffectiveness
AT danhu transcatheteraorticvalveimplantationversussurgicalaorticvalvereplacementinchinesepatientswithintermediateandhighsurgicalriskforaorticstenosisadecisionanalysisoneffectaffordabilityandcosteffectiveness
AT tongfengchen transcatheteraorticvalveimplantationversussurgicalaorticvalvereplacementinchinesepatientswithintermediateandhighsurgicalriskforaorticstenosisadecisionanalysisoneffectaffordabilityandcosteffectiveness
AT yipinzhao transcatheteraorticvalveimplantationversussurgicalaorticvalvereplacementinchinesepatientswithintermediateandhighsurgicalriskforaorticstenosisadecisionanalysisoneffectaffordabilityandcosteffectiveness
AT jiangtaocheng transcatheteraorticvalveimplantationversussurgicalaorticvalvereplacementinchinesepatientswithintermediateandhighsurgicalriskforaorticstenosisadecisionanalysisoneffectaffordabilityandcosteffectiveness
AT yuhaoliu transcatheteraorticvalveimplantationversussurgicalaorticvalvereplacementinchinesepatientswithintermediateandhighsurgicalriskforaorticstenosisadecisionanalysisoneffectaffordabilityandcosteffectiveness